The
pulmonary tuberculosis process as dependent on the disease form and the
therapy efficacy with the use of
Cycloferon in the treatment scheme were investigated. The study had two stages. At the first stage the data concerning 358 patients with primary
pulmonary tuberculosis and infiltration (93 patients) or degradation (89 patients) and 176 patients with pulmonary fibrocavernous
tuberculosis were analysed. At the second stage the efficacy of the treatment schemes applied to the patients with pulmonary fibrocavernous
tuberculosis was compared. The etiotropic
therapy intensive phase was applied to all the patients. Moreover, 56 patients (group 1) under the
therapy and rehabilitatinon were treated with
Cycloferon in a dose of 0.25 administered intramuscularly twice a week (not less than 16
injections for the course), 60 patients (group 2) were treated with Omega 3, 30 patients (group 3) were given the standard complex (
vitamins and tonics), 30 patients (group 4) were under the etiotropic
therapy alone. The following additional factors promoting progression and aggravation of the
tuberculosis process were confirmed: degradation at the time of the disease diagnosis, high resistance of the pathogen to antituberculosis drugs, low adherence to the treatment, social desadaptation and especially psychofunctional state of the patients. The use of
Cycloferon in the schemes of the intensive phase treatment of the primary fibrocavernous
tuberculosis resulted in reduction of the intoxication signs, bacteria isolation, positive dynamics of the cavity healing, lower lung infiltration and consequently high frequency of the treatment positive outcomes (94.1 ± 3.33%).